Please check your internet connection and try again.
# Amoxicillin-Clavulanate (Amox-Clav)
## Overview
Amoxicillin-clavulanate is a combination broad-spectrum penicillin-class antibiotic and a beta-lactamase inhibitor. The clavulanate component expands the spectrum of activity against beta-lactamase-producing bacteria (e.g., *S. aureus*, *H. influenzae*, *M. catarrhalis*).
## Primary Indications
Commonly used for acute bacterial rhinosinusitis, community-acquired pneumonia, animal/human bites, diabetic foot infections, and skin/soft tissue infections.
## Adult Dosing
* **Standard dosing:** 500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours.
* **Severe infections:** 2000 mg/125 mg (extended-release formulation) every 12 hours.
* *Note: Always base dosing on the amoxicillin component.*
## Pediatric Dosing
* **General Dosage:** 25–45 mg/kg/day (based on amoxicillin component) divided every 12 hours using 4:1 or 7:1 ratio formulations.
* **Recurrent/Resistant Otitis Media:** 80–90 mg/kg/day divided every 12 hours.
* **Max dose:** Do not exceed 875 mg of amoxicillin per dose.
## Dose Adjustments
* **Renal Impairment:** Adjustments required for CrCl < 30 mL/min. Avoid extended-release formulations (e.g., 2000 mg tablets) in severe renal impairment.
* **Hepatic Impairment:** Use with caution; monitor liver function due to risk of idiosyncratic cholestatic jaundice.
## Contraindications
* History of serious hypersensitivity reactions (anaphylaxis) to any penicillin or cephalosporin.
* History of cholestatic jaundice or hepatic dysfunction associated with previous amoxicillin-clavulanate use.
## Adverse Effects
* **Common:** Diarrhea (very common due to clavulanate), nausea, vomiting, abdominal pain, rash.
* **Serious:** Clostridioides difficile-associated diarrhea (CDAD), anaphylaxis, Stevens-Johnson syndrome, hepatotoxicity (rare).
## Key Drug Interactions
* **Probenecid:** Decreases renal tubular secretion of amoxicillin, increasing blood levels.
* **Warfarin:** May increase INR/risk of bleeding; monitor PT/INR closely when initiating or stopping therapy.
* **Methotrexate:** May decrease clearance of methotrexate, increasing risk of toxicity.
* **Oral Contraceptives:** May reduce efficacy (consider backup method, though clinical evidence is debated).
## Monitoring
* Monitor renal function (CrCl) prior to or during treatment for long-term or high-dose therapy.
* Monitor LFTs if signs of hepatic dysfunction occur.
* Observe for signs of hypersensitivity (rash, urticaria, wheezing).
* Assess for persistent diarrhea (rule out CDAD).
## Clinical Pearls
* **Administration:** Take with food to reduce gastrointestinal side effects.
* **Ratios matter:** Standard suspensions (e.g., 200 mg/5 mL vs 600 mg/5 mL) contain different ratios of clavulanate. Ensure the correct concentration is prescribed to avoid excessive clavulanate consumption (which increases diarrhea risk).
* **Formulation Warning:** 875 mg tablets and 2000 mg tablets provide different amounts of clavulanate; they are not interchangeable unit-for-unit.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, institutional guidelines, and drug compatibilities via official references such as Lexicomp, UpToDate, or the manufacturer's package insert before prescribing or administering medication.
